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a b s t r a c t
Since the development of an atrial pacing algorithm for preventing atrial ﬁbrillation (AF), approximately
20 years ago, many clinical trials have demonstrated the effectiveness of atrial pacing with respect to AF
prevention. Nevertheless, the actual effectiveness of AF suppression via atrial pacing remains under
debate, and no deﬁnitive conclusion has been reached. The AF suppression algorithms embedded in
pacemakers have not demonstrated an unequivocal clinical efﬁcacy that would support changing of the
guidelines to recommend such algorithms. In this review of studies conducted since 2006, we discuss the
efﬁcacies of these AF suppression algorithms and their usefulness in patients requiring pacemaker
implantation.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Atrial ﬁbrillation (AF) is a highly prevalent atrial arrhythmia
that affects approximately 10% of individuals older than 75 years
of age and tends to increase in prevalence with advancing age
[1–3]. Although AF itself is not life threatening, it is a risk factor for
stroke, and the AF-associated stroke mortality rate is high [4–6].
Antiarrhythmic agents are usually effective for treating AF; how-
ever, some cases are refractory to pharmacological agents.
Although various treatments for AF such as catheter ablation have
been used, perfect rhythm control is not easily achieved.
An atrial overdrive pacing algorithm for the prevention of AF
was initially reported by Murgatroyd et al. in 1994 [7], and other
alternative pacing algorithms have since been developed, includ-
ing post-premature atrial contraction (PAC) and post-exercise
response algorithms and atrial overdrive pacing [8–10,33].
Although many clinical trials have been conducted, the usefulness
of AF control algorithms has remained a matter of debate during
the past 20 years [8–16]. Additionally, none of the pacemaker
guidelines includes an AF suppression algorithm as a standard
programming feature for AF prevention in pacemaker patients.
The stated reason is that pacemaker-embedded AF suppression
algorithms have not demonstrated unequivocal clinical efﬁcacy.
In this review, we summarize the previous clinical trials, char-
acterize the efﬁcacy of atrial pacing for AF prevention, and discuss
the practical clinical applications of this algorithm.
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2. Prevalence and impact of AF in clinical practice
AF is the most common arrhythmia worldwide, and its pre-
valence increases with age; AF occurs in approximately 10% of the
general population older than 75 years of age [1–3]. The pre-
valence of sick sinus syndrome or atrioventricular block, which
requires pacemaker implantation, also increases with age [17,18].
Asymptomatic AF episodes are detected in approximately 10% of
pacemaker recipients, an higher incidence than that observed in
the general population [19–21]. AF poses a signiﬁcant risk of
stroke and systemic thromboembolism. Stroke resulting from a
large cerebral infarction consequent to a left atrial appendage
thrombus is the most severe complication of AF and is associated
with a high mortality rate [22,23]. Annually, AF is responsible for
20% of all strokes. Strong evidence suggests that anticoagulant
therapy could reduce the annual incidence of stroke in patients
with AF; therefore, AF patients should certainly be treated with
anticoagulation agents to prevent stroke [24]. However, antic-
oagulation therapy is underused in clinical practice because of the
difﬁculty associated with drug administration and the risk of
bleeding complications [25]. Nevertheless, AF prevention should
be given the utmost priority.
3. Beneﬁt of dual-chamber pacing for AF prevention
Several studies have demonstrated that dual-chamber pacing,
through which ventricular pacing can be minimized, is superior to
single-chamber ventricular pacing in terms of reducing the inci-
dence of AF [26–31]. Atrial (atrial–atrial interval; AAI) and phy-
siologic pacing (dual-chamber pacing, dual-chamber sensing, dual
response, and rate-adaptive; DDDR) avoid atrioventricular dyssyn-
chrony, which is associated with increased atrial pressure. The
Mode Selection Trial (MOST) study [32] demonstrated a linear
increase in the risk of AF up to cumulative ventricular pacing rates
of approximately 80–85% in the DDDR and ventricular pacing,
ventricular sensing, inhibition response and rate-adaptive (VVIR)
modes (Fig. 1). Nielsen et al. [33] compared the AAI and DDDR
modes by observing changes in the left atrial (LA) diameter and
left ventricular fractional shortening (LVFS). In the DDDR mode,
the LA diameter increased signiﬁcantly (po0.05) and the LVFS
decreased signiﬁcantly (po0.01) [33]. Additionally, AF occurred
signiﬁcantly less often in the AAI mode. Therefore, by increasing
the atrial stress associated with ventricular dyssynchrony, ventri-
cular pacing might increase the risk of AF even when AV syn-
chrony has been preserved. A large, randomized trial conducted by
Connolly et al. [29] reported a signiﬁcantly lower annual incidence
of AF in the physiologic pacing group (5.3%) than in the ventricular
pacing group (6.6%).
4. AF suppression algorithm and prevention mechanism
The atrial overdrive pacing algorithm is the most commonly
used algorithm for AF prevention. Other pacing strategies have
also been developed, including atrial pacing in response to atrial
premature beats (post-PAC response), pacing in response to
exercise (post-exercise rate control), and post-mode-switch pacing
(Fig. 2) [34]. The suppression of potential AF triggers mechanisms,
including long pauses after premature beats and atrial refractory
period dispersion, through the elimination of pauses consequent
to bradycardia or the reduction of premature beats is considered
the mechanism responsible for overdrive pacing-mediated AF
prevention. Atrial pacing has also been suggested to prevent AF
by improving the synchronization of atrial depolarization. There-
fore, alternative-site pacing such as Bachmann's bundle pacing,
atrial septum pacing, and multisite pacing have been used to
prevent AF in several pacing trials [16,35–39]. Several of these
studies have demonstrated the efﬁcacy of alternative site pacing
versus conventional right atrial appendage pacing for reducing
the incidence of AF; however, other studies have not demonstrated
similar efﬁcacies. Therefore, alternative-site pacing currently
remains controversial in clinical settings.
Fig. 1. Kaplan–Meier curves of freedom from documented incidences of atrial
ﬁbrillation (AF) as shown by the cumulative percentages of ventricular pacing (cum
%VP) during the ﬁrst 30 days. (A) DDDR mode; (B) VVIR mode (reproduced with
permission: reference [31]).
Fig. 2. Schematic view of 4 atrial ﬁbrillation prevention pacing algorithms
(reproduced with permission: reference [33]).
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5. Clinical trials of AF suppression algorithms
Many randomized clinical trials of AF suppression algorithms
were conducted during the previous decade. Most of these trials
demonstrated the efﬁcacy of atrial pacing for AF prevention;
however, several studies yielded contrasting results. As a result,
a consensus has not been reached regarding the utility of these
algorithms. The study conditions, including the study populations,
patients' ages, concomitant medications, pacing strategies, and
study endpoints, varied among the trials. In addition, the study
groups were fairly small. In 2005, Knight et al. summarized data
obtained from the clinical trials of various AF prevention algo-
rithms and published the ﬁndings as an American Heart Associa-
tion science advisory [40]. Furthermore, Mizutani summarized the
various pacing techniques used for AF prevention, including the
pacing modes and pacing site or sites [41]. Therefore, we decided
to review the clinical trials that were published in 2006 and
thereafter. These trials are summarized in Table 1. The study
patients ranged in age from 50 to 73 years. A majority of the trials
compared atrial pacing in the AF suppression algorithm ON
condition vs. the OFF condition.
Shuchert et al. [13] used 4 different atrial pacing algorithms for
AF prevention: pace conditioning (continuous dynamic overdrive
pacing) and 3 triggered pacing algorithms (PAC suppression, post-
PAC response, and post-exercise response). The patients were
randomly selected to undergo triggered atrial overdrive pacing
alone (3 pacing functions; “triggered group”) or a combination of
continuous and triggered atrial overdrive pacing (4 pacing func-
tions; “combined group”). Several patients in the combined group
could not tolerate the high-rate pacing and were consequently
excluded from the evaluation. The percentage of patients under-
going atrial pacing in the combined group was 97%, and the AF
burden in this group was 2.1%. The percentage of atrial pacing in
the triggered group was signiﬁcantly lower at 85%; however, the
AF burden was also signiﬁcantly lower at 0.1%, thus demonstrating
the pacing algorithm to be effective for AF prevention. In contrast,
Camm et al. [10] had previously used the same device (Selection
9000, Vitatron, Maastricht, Netherlands) and had been unable to
conﬁrm the effectiveness of preventative atrial pacing in a very
similar population. The discrepant results between these 2 trials
highlight the difﬁculty in establishing convincing evidence for the
efﬁcacy of preventative atrial pacing. Most trials have selected 90
beats per minute (bpm) as the upper limit for continuous
overdrive pacing because pacing above 90 bpm cannot be toler-
ated for a long period. Only 1 relatively early study, conducted by
Pürefellner et al. [9], used a relatively high pacing rate of 90 bpm
or 120 bpm for 10 min of post-mode-switch overdrive pacing
(PMOP), and the percentage of atrial pacing in that study was
high in comparison to that of other trials. Given the results of that
trial, the authors recommended programming the device at a
PMOP rate of 90 bpm and concluded that PMOP could effectively
prevent the early occurrence of AF and that the pacing rate was
well tolerated. In contrast, Sulke et al. used atrial pacing at an
upper limit of 80 bpm and did not observe that atrial pacing could
effectively reduce the AF burden. The results of these studies
suggest that the atrial pacing rate for AF prevention should be
sufﬁciently high to inhibit the AF triggers.
In a study of the atrial pacing preference (APP) algorithm,
Ogawa et al. [12] randomly programmed pacemakers as APP OFF
and APP ON at 3 different settings (8, 16, and 33 cycles). The
authors found that the most effective setting differed according to
the patient and thus concluded that this therapy necessitated the
determination of the “optimal” setting for each patient. The
efﬁcacy of any atrial pacing algorithm depends on background
factors such as hypertension, diabetes, and any other condition
that could promote tissue ﬁbrosis. Furthermore, the effect of the T
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algorithm is inﬂuenced by programming options such as the
atrioventricular delay, the pacing rate, and the number of pacing
cycles. Garrigue et al. [42] used programmed increases in the
lower rate from 55 ppm to 72 ppm, along with increases in the
atrial pacing rate from 32% to 67%, to achieve signiﬁcant reduc-
tions in the number and duration of paroxysmal AF episodes. That
trial demonstrated that a relatively high atrial pacing rate might be
necessary to inhibit the AF triggers and that it would also be
necessary to set the pacemaker rate according to the tolerance of
each patient.
The ventricular pacing rates differed greatly among the trials
(from 11% to 93%). Interestingly, the ventricular pacing rate was
not associated with the effectiveness of AF suppression. In a
randomized trial, Gold et al. [14] demonstrated a reduction in
the AF burden with a right ventricular pacing rate of 96%.
However, these ventricular pacing data do not agree with other
reported evidence suggesting that ventricular pacing is inferior to
atrial pacing for reducing the incidence of AF. Overall, atrial pacing
appears to play a more important role than ventricular pacing in
this setting. Most trials had a relatively short follow-up period and
did not produce consistent results.
An interesting ﬁnding of the Study for Atrial Fibrillation
Reduction (SAFARI) trial was that the AF reduction beneﬁt was
greater among patients with a high baseline AF burden than
among those with a relatively low baseline AF burden [14]. This
ﬁnding might possibly explain why a subsequent large trial [15]
failed to conﬁrm the efﬁcacy of an AF suppression algorithm in
patients with no history of AF. That very large randomized study of
2343 patients without a history of AF reported that continuous
atrial overdrive pacing did not prevent new-onset AF, was poorly
tolerated, and accelerated pulse generator battery depletion. Data
from the trial with the longest follow-up period [16] revealed that
AF prevention pacing was effective for at least 66 months in more
than 50% of the study patients (Fig. 3). An overall assessment of
the long-term effects of AF prevention pacing is difﬁcult to
conduct because the general conditions of the patients and their
surrounding circumstances vary on a case-by-case basis because of
aging, blood pressure, and many other factors. AF mechanisms
such as the PAC trigger might also inﬂuence the responses to
pacing-based AF suppression therapies.
Most trials have demonstrated the short-term effectiveness of
the AF prevention pacing algorithm. We believe that all cardiolo-
gists should endeavor to adopt AF prevention pacing algorithms in
their clinical practices, given that the algorithm can be easily
programmed to the ON or OFF mode as needed. Currently, there is
no consensus regarding the prevention of AF with atrial pacing via
AF suppression algorithms. However, most trials have demon-
strated the safety of this treatment modality, and the character-
istics of patients who respond to these atrial pacing algorithms can
be evaluated.
6. Summary
A lack of conﬁrmatory data from an adequate number of large
randomized trials is among the reasons for the lack of a gold
standard AF suppression therapy in pacemaker recipients. How-
ever, the safety of atrial pacing algorithms for AF prevention has
been demonstrated, and these algorithms have been shown to
be truly effective in certain cases. Symptomatic AF greatly affects
the patient's quality of life, and asymptomatic AF is an important
cause of thromboembolism. Given the risk of AF complications, it
might be beneﬁcial to use an AF suppression algorithm in patients
with a history of AF and indications for permanent pacemaker
implantation. However, each pacemaker should be programmed
carefully to ensure the most effective or so-called “optimal”
setting. A full understanding of all cases in which this therapy
might be effective is advised to ensure the appropriate clinical
application of this therapy.
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